Relationship Between Bilirubin Levels and Heart Rate Recovery in Polycystic Ovary Syndrome Patients

Year 2019, Volume: 5 Issue: 2, 74 - 85, 20.06.2019

Emin Asoğlu

Abstract

Aim: Bilirubin is a final product of heme metabolism 

and also has antioxidant properties. But there is no 

information on the effect of bilirubin in the 

pathogenesis of in Polycystic Ovary Syndrome 

(PCOS). The goal of the present study was to 

investigate the relationship between bilirubin levels, 

PCOS and heart rate recovery (HRR).  

Material and Methods: Subjects were included in 

this study from our center’s Department of 

Gynecology & Obstetrics between March 2012 and 

May 2013. Serum bilirubin levels and other blood 

parameters in at least 12-hour fasting states were 

determined. Exercise stress test was performed on all 

patients and control participants

Results: Thirty four patients with a diagnosis of 

PCOS aged younger than 40 year and twenty seven 

healthy women matched by age, BMI, heart rate and 

blood pressure were included in the study. Total 

bilirubin levels in PCOS group were significantly 

lower than the control group. The HRR was 

significantly decreased in women with PCOS 

compared the control group. In the Pearson 

correlation test, HRR was significantly correlated 

with homeostasis model assessment insulin resistance 

(HOMA-IR) index and bilirubin levels. 

Conclusions:  The bilirubin levels may affect HRR in 

PCOS patients. Therefore, in the treatment of PCOS 

patients, oxidative stress and its harmful effects 

should be considered. 

Keywords

Bilirubin, heart rate recovery, polycystic ovary syndrome, exercise test

References

• erences 1. Sanchón R, Gambineri A, Alpañés M, Martníez-Garcaí MÁ, et al. HF. Prevalence of functional disorders of androgen excess in unselected premenopausal women: a study in blood donors. Hum Reprod 2012;27:1209–16. 2. Barber TM, Franks S. The link between polycystic ovary syndrome and both {Type} 1 and {Type} 2 diabetes mellitus: what do we know today? Women’s Heal 2012;8:147–54. 3. Bentley-Lewis R, Seely E, Dunaif A. Ovarian hypertension: polycystic ovary syndrome. Endocrinol Metab Clin 2011;40:433–49. 4. Chang C-Y, Chen M-J, Yang W-S, Yeh C-Y, et al. Hypoadiponectinemia: A useful marker of dyslipidemia in women with polycystic ovary syndrome. Taiwan J Obstet Gynecol 2012;51:583–90. 5. Yaralı H, Yıldırır A, Aybar F, Kabakçı G, et al. Diastolic dysfunction and increased serum homocysteine concentrations may contribute to increased cardiovascular risk in patients with polycystic ovary syndrome. Fertil Steril 2001;76:511–6. 6. Verit FF, Erel O. Oxidative stress in nonobese women with polycystic ovary syndrome: correlations with endocrine and screening parameters. Gynecol Obstet Invest 2008;65:233–9. 7. Mohamadin AM, Habib FA, Elahi TF. Serum paraoxonase 1 activity and oxidant/antioxidant status in {Saudi} women with polycystic ovary syndrome. Pathophysiology 2010;17:189–96. 8. Enli Y, Fenkci SM, Fenkci V, Oztekin O. Serum {Fetuin}-{A} levels, insulin resistance and oxidative stress in women with polycystic ovary syndrome. Gynecol Endocrinol 2013;29:1036–9. 9. Hoeldtke RD, Bryner KD, VanDyke K. Oxidative stress and autonomic nerve function in early type 1 diabetes. Clin Auton Res 2011;21:19–28. 10. Ziegler D, Sohr CGH, Nourooz-Zadeh J. Oxidative stress and antioxidant defense in relation to the severity of diabetic polyneuropathy and cardiovascular autonomic neuropathy. Diabetes Care 2004;27:2178–83. 11. Imai K, Sato H, Hori M, Kusuoka H, et al. Vagally mediated heart rate recovery after exercise is accelerated in athletes but blunted in patients with chronic heart failure. J Am Coll Cardiol 1994;24:1529–35. 12. Cole CR, Blackstone EH, Pashkow FJ, Snader CE, et al. Heart-rate recovery immediately after exercise as a predictor of mortality. N Engl J Med 1999;341:1351–7. 13. Schwartz PJ, La MTR, Vanoli E. Autonomic nervous system and sudden cardiac death. {Experimental} basis and clinical observations for post-myocardial infarction risk stratification. Circulation 1992;85:I77--91. 14. Tekin G, Tekin A, Kılıçarslan EB, Haydardedeoğlu B, et al. Altered autonomic neural control of the cardiovascular system in patients with polycystic ovary syndrome. Int J Cardiol 2008;130:49–55. 15. Giallauria F, Palomba S, Manguso F, Vitelli A, et al. Abnormal heart rate recovery after maximal cardiopulmonary exercise stress testing in young overweight women with polycystic ovary syndrome. Clin Endocrinol (Oxf) 2008;68:88–93. 16. Jansen T, Daiber A. Direct antioxidant properties of bilirubin and biliverdin. {Is} there a role for biliverdin reductase? Front Pharmacol 2012;3:30. 17. Tinkel J, Hassanain H, Khouri SJ. Cardiovascular antioxidant therapy: a review of supplements, pharmacotherapies, and mechanisms. Cardiol Rev 2012;20:77–83. 18. Oh SW, Lee ES, Kim S, Na KY, et al. Bilirubin attenuates the renal tubular injury by inhibition of oxidative stress and apoptosis. BMC Nephrol 2013;14:105. 19. Gul M, Uyarel H, Ergelen M, Akgul O, et al. Prognostic value of total bilirubin in patients with {ST}-segment elevation acute myocardial infarction undergoing primary coronary intervention. Am J Cardiol 2013;111:166–71. 20. Turfan M, Duran M, Poyraz F, Yayla C, et al. Inverse relationship between serum total bilirubin levels and severity of disease in patients with stable coronary artery disease. Coron Artery Dis 2013;24:29–32. 21. Katsiki N, Karagiannis A, Mikhailidis DP. Diabetes, bilirubin and amputations: is there a link? Diabetologia 2013;56:683–5. doi:10.1007/s00125-013-2840-1. 22. Choi S-W, Lee Y-H, Kweon S-S, Song H-R, et al. Association between total bilirubin and hemoglobin {A}1c in {Korean} type 2 diabetic patients. J Korean Med Sci 2012;27:1196–201. doi:10.3346/jkms.2012.27.10.1196.